NeoPharm CO. LTD (092730) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of NeoPharm CO. LTD stock KRW 28,699, price KRW 23,500, upside +22.1%, quality 67 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 6,905 KRW – 25,450 KRW · fair‑value band 18,108 KRW – 40,808 KRW · the 23,500 KRW price screens below the 28,699 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow NeoPharm CO. in your weekly email
Every Wednesday you see whether NeoPharm CO. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
NeoPharm CO., LTD. manufactures and sells skin care products in South Korea.
Show moreShow less
The company offers Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand; products for sensitive, dry, oily, or trouble-prone skin under the ZEROID brand; body moisturizers under the Derma-B brand; and sport care products for athletes under the MISSION ATHELETCARE brand.
NeoPharm CO., LTD. was founded in 2000 and is headquartered in Daejeon, South Korea.
Stock analysis
NeoPharm CO. LTD (092730) currently trades at 23,500 KRW, while our model-based Fair Value estimate is 28,699 KRW, implying the stock looks roughly 18% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 35,793 KRW per share, and 13 of the 26 models we run sit above the 23,500 KRW price.
Bear case: the Dividend Discount group reads lowest at 6,550 KRW, and 13 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 18,108 KRW (bear) to 40,808 KRW (bull), the price of 23,500 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Consumer Non-Cyclicals sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
NeoPharm CO. LTD reported revenue of 132B KRW in FY2025 versus 87.9B KRW in FY2021, a compound +10.7%/yr. Reported net income was 27.8B KRW in FY2025, compounding +12.0%/yr from FY2021.
Key figures
Market cap 368B KRW (≈ $272M) Micro · P/S ratio 4.02 · Dividend yield 3.5% · Net margin 21.0% · Return on equity 1,439% · Return on assets (EBIT) 13.9% (5-year average) · Operating margin 24.9% · Revenue (TTM) 86.8B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 77 out of 100 (medium confidence).
What moves the price
The share trades about 8% below its 52-week high and 49% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Non-Cyclicals peers we cover trades at −26% fair-value upside, at 22%, 092730 screens cheaper than that median.
Fair Value models
Bear18,108 KRWFair Value 28,699 KRWBull40,808 KRW
Price 23,500 KRW · Upside +22.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.83/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+11.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
Start year 2020 (pandemic). Over 10 years: +13.9% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.2%
’12
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−1.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.2%
Dividend (yield on the price)3.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−5.2% vs 5.0%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.27% → 22%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +0.1% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Personal & Household Products & Services” was too small, so the broader sector is used.)Consumer Staples · 1694 stocks
Beats the sector median on 7/11 measures
Overall it ranks above its sector peers.
Valuation
Quality Score67 · Top 25%
Fair Value upside+22.1% · Above median
Profitability
Return on assets12.8% · Top 25%
Net margin (12 months)21.0% · Top 25%
Operating margin (12 months)24.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)−3.2% · Bottom 25%
Dividend yield (12 months)3.5% · Above median
Valuation Multiplesvs Consumer Staples median · lower = cheaper
P/B1.88× · Pricier than median
P/S (12 months)4.23× · Priciest 25%
Price / free cash flow (fiscal year)13.6× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is NeoPharm CO. LTD (092730) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 28,699 KRW versus a price of 23,500 KRW, about +22% upside (undervalued).
What is the fair value of 092730?
Our model-based fair value for NeoPharm CO. LTD is 28,699 KRW (as of Nov 3, 2026), built from audited fundamentals. The current price: 23,500 KRW.
What is the quality score of 092730?
NeoPharm CO. LTD has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NeoPharm CO. LTD (092730)?
Our model-based price target is the fair value of 28,699 KRW (as of Nov 3, 2026) from 26 valuation models. Cautious scenario 18,108 KRW, optimistic scenario 40,808 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the NeoPharm CO. LTD stock forecast for 2026?
Our models put fair value at 28,699 KRW, about +22% upside versus a price of 23,500 KRW (undervalued). Cautious scenario 18,108 KRW, optimistic scenario 40,808 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of NeoPharm CO. LTD (092730)?
NeoPharm CO. LTD reported trailing-twelve-month revenue of about 86.8B KRW (latest available figure, as of Nov 3, 2026).
Does NeoPharm CO. LTD pay a dividend?
NeoPharm CO. LTD currently shows a dividend yield of 3.51% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of NeoPharm CO. LTD (092730)?
NeoPharm CO. LTD has a dividend yield of 3.5%. A dividend has been paid every year since at least 2007. Our assessment: Safety not assessed. Payout ratio and cash coverage are not available, so we do not judge how safe this dividend is.
What growth is priced into NeoPharm CO. LTD (092730)?
For today's price to be fair in a discounted-cash-flow model, NeoPharm CO. LTD would have to grow free cash flow by +2.1 % per year for five years (discount rate 12.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.1 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of 092730 use?
Our models discount NeoPharm CO. LTD at 12.9 %: a base by market capitalisation (micro), damped by beta 0.93, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For NeoPharm CO. LTD that is +2.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.9 %) and the same formula as our fair value.
How much growth has NeoPharm CO. LTD (092730) delivered so far?
Over the past 5 years revenue at NeoPharm CO. LTD grew +10.1 % a year. The price currently implies free-cash-flow growth of +2.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of NeoPharm CO. LTD (092730) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into NeoPharm CO. LTD (+2.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of NeoPharm CO. LTD (092730)?
The free-cash-flow yield on the price is 7.34 %: that much free cash flow NeoPharm CO. LTD produces per unit of market value. When it exceeds the discount rate of our models (12.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of NeoPharm CO. LTD (092730)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NeoPharm CO. LTD it is 28,699 KRW per share (as of Nov 3, 2026), against a price of 23,500 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is NeoPharm CO. LTD stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 092730 trades below its calculated fair value: price 23,500 KRW, fair value 28,699 KRW, a gap of about +22% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 092730?
No. The price is what the market pays today (23,500 KRW); the fair value is what the company's own numbers justify (28,699 KRW). For NeoPharm CO. LTD the two are 5,199 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is NeoPharm CO. LTD worth?
The market values NeoPharm CO. LTD at about 368B KRW (market capitalisation, as of Nov 3, 2026). Per share that is 23,500 KRW; our models calculate a fair value of 28,699 KRW per share.
What do the bullish and bearish scenarios say about 092730?
Our models span a range for NeoPharm CO. LTD: cautious scenario 18,108 KRW, base 28,699 KRW, optimistic 40,808 KRW per share (as of Nov 3, 2026, price 23,500 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 092730 from its 52-week high?
NeoPharm CO. LTD trades at 23,500 KRW, about 8% below its 52-week high of 25,450 KRW and 49% above the low of 15,760 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 28,699 KRW is for.
Which stocks are comparable to NeoPharm CO. LTD?
From the same area (Consumer Non-Cyclicals) we also value HYUNDAI BIOLAND Co, Csa Cosmic Co, FB, JGS, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NeoPharm CO. LTD stock attractive at the current price?
The data as of Nov 3, 2026: price 23,500 KRW, calculated fair value 28,699 KRW (+22%), Quality Score 67/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 092730 calculated?
We run NeoPharm CO. LTD through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 28,699 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. NeoPharm CO. LTD currently trades 18% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NeoPharm CO. LTD (092730)?
The closing price on Nov 6, 2026 was 23,500 KRW. Our model-based fair value is 28,699 KRW, about +22% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NeoPharm CO. LTD right now?
Solid quality (67/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (18,108 KRW to 40,808 KRW) leaves room in how you read the outcome.
Key figures of NeoPharm CO. LTD
How large is the market capitalisation of NeoPharm CO. LTD (092730)?
The market capitalisation of NeoPharm CO. LTD is 368B KRW (≈ $272M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NeoPharm CO. LTD (092730)?
The price-to-sales ratio of NeoPharm CO. LTD is 4.02 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of NeoPharm CO. LTD (092730)?
The dividend yield of NeoPharm CO. LTD is 3.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of NeoPharm CO. LTD (092730)?
The net margin of NeoPharm CO. LTD is 21.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NeoPharm CO. LTD (092730)?
The return on equity (ROE) of NeoPharm CO. LTD is 1,439% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NeoPharm CO. LTD (092730)?
On an EBIT basis the return on assets of NeoPharm CO. LTD is 13.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NeoPharm CO. LTD (092730)?
The operating margin of NeoPharm CO. LTD is 24.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NeoPharm CO. LTD (092730)?
Revenue at NeoPharm CO. LTD is growing −3.2% versus a year earlier (3y avg +15.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at NeoPharm CO. LTD (092730)?
Earnings per share at NeoPharm CO. LTD are growing +28.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch NeoPharm CO. LTD in the live analysis
One click puts NeoPharm CO. LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 3, 2026